Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
Promotie: Follow-up na behandeling van darmkanker
apr 2024 | Maag-darm-leveroncologie